Back to Search
Start Over
[Surgical Treatment of Hypopharyngeal Carcinoma, Neck Dissection and Adjuvant Postoperative Therapy of Oropharyngeal and Hypopharyngeal Cancer: Recommendations of the current S3 Guideline - Part II].
- Source :
-
Laryngo- rhino- otologie [Laryngorhinootologie] 2024 Oct; Vol. 103 (10), pp. 734-753. Date of Electronic Publication: 2024 Oct 01. - Publication Year :
- 2024
-
Abstract
- Part II of the S3 guideline report deals with the surgical treatment of hypopharyngeal carcinoma, neck dissection for oropharyngeal and hypopharyngeal carcinomas and adjuvant therapy options. Primary surgical therapy ± adjuvant radio- or radiochemotherapy and primary radio- or radiochemotherapy are established as primary therapies for local-regional hypopharyngeal carcinomas. Direct randomized comparisons of both basic therapeutic procedures were never conducted. Available registry data show a worse prognosis of hypopharyngeal carcinoma compared to oropharyngeal carcinomas in all locoregional tumor stages, regardless of the treatment method. For T1N0-T2N0 squamous cell carcinoma of the hypopharynx, there are no relevant differences in overall survival and locoregional relapse rate between primary surgical and primary non-surgical treatment. Primary surgical therapy ± adjuvant radiotherapy or radiochemotherapy and primary radiotherapy or radiochemotherapy are established as primary therapies for advanced but locoregionally limited hypopharyngeal carcinomas. Neck dissection is an integral part of the primary surgical treatment of oropharyngeal and hypopharyngeal cancer. There are only a few randomized studies on non-surgical organ preservation for advanced hypopharyngeal cancer as an alternative to pharyngolaryngectomy, but these have led to the recommendation of alternative concepts in the new guideline. The indication and implementation of postoperative adjuvant radiotherapy and radiochemotherapy for hypopharyngeal carcinoma do not differ from those for HPV/p16-negative and -positive oropharyngeal carcinoma.<br />Competing Interests: Erklärung zu finanziellen Interessen Forschungsförderung erhalten: nein; Honorar/geldwerten Vorteil für Referententätigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfänger: nein; Patent/Geschäftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an Firma (Nicht‐Sponsor der Veranstaltung): nein; Patent/Geschäftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an Firma (Sponsor der Veranstaltung): nein Erklärung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.<br /> (Thieme. All rights reserved.)
- Subjects :
- Humans
Radiotherapy, Adjuvant
Combined Modality Therapy
Chemoradiotherapy, Adjuvant
Carcinoma, Squamous Cell pathology
Carcinoma, Squamous Cell surgery
Carcinoma, Squamous Cell therapy
Survival Rate
Prognosis
Hypopharyngeal Neoplasms pathology
Hypopharyngeal Neoplasms surgery
Hypopharyngeal Neoplasms therapy
Neck Dissection
Oropharyngeal Neoplasms surgery
Oropharyngeal Neoplasms pathology
Oropharyngeal Neoplasms therapy
Neoplasm Staging
Subjects
Details
- Language :
- German
- ISSN :
- 1438-8685
- Volume :
- 103
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Laryngo- rhino- otologie
- Publication Type :
- Academic Journal
- Accession number :
- 39353451
- Full Text :
- https://doi.org/10.1055/a-2223-4098